#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Greece Spain

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia France Germany Greece Ireland +3

  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Poland

  • Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark France Germany Greece Italy Poland +1

  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia France Germany Greece +4

  • Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia Denmark France Germany Hungary +4

  • Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Portugal Spain